Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Author Profile


Anna Hemnes, PhD

 

Institution

Division of Pulmonary and Critical Care Medicine
Department of Medicine and Division of Medical Genetics
Department of Pediatrics
Vanderbilt University
School of Medicine
Nashville, TN

Summary

Dr. Anna R. Hemnes received her undergraduate degree from Columbia University in 1995 and her M.D. from Johns Hopkins in 1999. She completed her Internal Medicine residency and fellowship in Pulmonary and Critical Care Medicine at Johns Hopkins as well. She received advanced training in pulmonary vascular disease at Vanderbilt and has incorporated this interest into her research focus: physiology of pulmonary vascular disease. Her laboratory investigates how the right ventricle hypertrophies and fails in the load stress of pulmonary hypertension and the influence of gender on this phenotype. She is also interested in the non-invasive diagnosis and evaluation of pulmonary vascular disease ranging from pulmonary embolism to pulmonary arterial and venous hypertension. 

Board Certifications

Critical Care Medicine - American Board of Internal Medicine, 2007
Pulmonary Disease - American Board of Internal Medicine, 2006
Internal Medicine - American Board of Internal Medicine, 2002

Education

MD - Johns Hopkins University
Fellowship - Vanderbilt University Medical Center
Fellowship - Johns Hopkins Hospital and Health System
Internship - Johns Hopkins Hospital and Health System
Residency - Johns Hopkins Hospital and Health System

Selected Publications

  1. Austin, ED, Hamid, R, Hemnes, AR, Loyd, JE, Blackwell, T, Yu, C, Phillips Iii, JA, Gaddipati, R, Gladson, S, Gu, E, West, J, Lane, KB. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ, 3(1), 6, 2012. PMCID:3310853
  2. Brittain, EL, Hemnes, AR, Keebler, M, Lawson, M, Byrd, BF, Disalvo, T. Right ventricular plasticity and functional imaging. Pulm Circ, 2(3), 309-26, 2012.
  3. Fessel, JP, Hamid, R, Wittmann, BM, Robinson, LJ, Blackwell, T, Tada, Y, Tanabe, N, Tatsumi, K, Hemnes, AR, West, JD. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ, 2(2), 201-13, 2012. PMCID:3401874
  4. Hemnes, AR, Maynard, KB, Champion, HC, Gleaves, L, Penner, N, West, J, Newman, JH. Testosterone negatively regulates right ventricular load stress responses in mice. Pulm Circ, 2(3), 352-8, 2012.
  5. Johnson, JA, Hemnes, AR, Perrien, DS, Schuster, M, Robinson, LJ, Gladson, S, Loibner, H, Bai, S, Blackwell, TR, Tada, Y, Harral, JW, Talati, M, Lane, KB, Fagan, KA, West, J. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol, 302(5), L474-84, 2012. PMCID:3310853
  6. Larkin, EK, Newman, JH, Austin, ED, Hemnes, AR, Wheeler, L, Robbins, IM, West, JD, Phillips, JA, Hamid, R, Loyd, JE. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med, 186(9), 892-6, 2012.
  7. Pugh, ME, Buchowski, MS, Robbins, IM, Newman, JH, Hemnes, AR. Physical Activity Limitation as Measured by Accelerometry in Pulmonary Arterial Hypertension. Chest, , , 2012. PMCID:3401874
  8. West, J, Niswender, KD, Johnson, JA, Pugh, ME, Gleaves, L, Fessel, JP, Hemnes, AR. A potential role for Insulin resistance in experimental pulmonary hypertension. Eur Respir J, , , 2012.
  9. Austin, ED, Menon, S, Hemnes, AR, Robinson, LR, Talati, M, Fox, KL, Cogan, JD, Hamid, R, Hedges, LK, Robbins, I, Lane, K, Newman, JH, Loyd, JE, West, J. Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression. Pulm Circ, 1(3), 389-98, 2011. PMCID:3224431
  10. Hemnes, AR, Pugh, ME, Newman, AL, Robbins, IM, Tolle, J, Austin, ED, Newman, JH. End tidal CO(2) tension: pulmonary arterial hypertension vs pulmonary venous hypertension and response to treatment. Chest, 140(5), 1267-73, 2011. PMCID:3112229
  11. Johnson, JA, West, J, Maynard, KB, Hemnes, AR. ACE2 improves right ventricular function in a pressure overload model. PLoS One, 6(6), e20828, 2011. PMCID:3112229
  12. Lane, KL, Talati, M, Austin, E, Hemnes, AR, Johnson, JA, Fessel, JP, Blackwell, T, Mernaugh, RL, Robinson, L, Fike, C, Roberts, LJ, West, J. Oxidative injury is a common consequence of BMPR2 mutations. Pulm Circ, 1(1), 72-83, 2011. PMCID:3167174
  13. Pugh, ME, Robbins, IM, Rice, TW, West, J, Newman, JH, Hemnes, AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant, 30(8), 904-11, 2011. PMCID:3129440
  14. Robbins, IM, Hemnes, AR, Gibbs, JS, Christman, BW, Howard, L, Meehan, S, Cabrita, I, Gonzalez, R, Oyler, T, Zhao, L, Du, RH, Mendes, LA, Wilkins, MR. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res, 37(1), 26-34, 2011. PMCID:3077035
  15. Hemnes, AR, Newman, AL, Rosenbaum, B, Barrett, TW, Zhou, C, Rice, TW, Newman, JH. Bedside end-tidal CO2 tension as a screening tool to exclude pulmonary embolism. Eur Respir J, 35(4), 735-41, 2010. PMCID:2757639
  16. Pugh, ME, Hemnes, AR. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl), 6(2), 285-96, 2010. PMCID:2853883
  17. Pugh, ME, Hemnes, AR. Pulmonary hypertension in women. Expert Rev Cardiovasc Ther, 8(11), 1549-58, 2010. PMCID:3077035
  18. Pugh, ME, Hemnes, AR. Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man. Int J Clin Pract Suppl, (168), 5-13, 2010. PMCID:2965027
  19. Hemnes, AR, Bertram, A, Sisson, SD. Impact of medical residency on knowledge of asthma. J Asthma, 46(1), 36-40, 2009. PMCID:2757639
  20. Hemnes, AR, Doyle, TP, Janssen, D, Robbins, IM. Congenital pulmonary artery stenoses masquerading as chronic thromboembolic disease. J Heart Lung Transplant, 28(10), 1110-1, 2009. PMCID:2757639
  21. Hemnes, AR, Forfia, PR, Champion, HC. Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography. Int J Clin Pract Suppl, (162), 4-19, 2009. PMCID:2757639
  22. Hemnes, AR, Robbins, IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl, 15(1), 15-9, 2009. PMCID:2716716
  23. Robbins, IM, Newman, JH, Johnson, RF, Hemnes, AR, Fremont, RD, Piana, RN, Zhao, DX, Byrne, DW. Association of the metabolic syndrome with pulmonary venous hypertension. Chest, 136(1), 31-6, 2009. PMCID:2716716
  24. Hemnes, AR, Champion, HC. Right heart function and haemodynamics in pulmonary hypertension. Int J Clin Pract Suppl, (160), 11-9, 2008. PMCID:2716716

 


Profile Photo

Courses

  • WHO Group 1 PH (PAH) Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension (PH) characterized by increases in both pulmonary arterial pressure and pulmonary vascular resistance (PVR). This educational activity will help participants a) differentiate PAH from other forms of PH; b) integrate diagnostic tests to improve accuracy in PAH diagnosis; c) describe risk factors for developing PAH; and d) recognize outcome differences between associated PAH and idiopathic/heritable PAH.

Journal Articles

  • Chasing Pulmonary Hypertension After years of effort, investigators at Vanderbilt and Columbia found the gene for heritable pulmonary hypertension (PH) nearly simultaneously in the year 2000.1,2 Mutations in the so-called bone morphogenetic protein receptor type 2 (BMPR2) are now known to be responsible for about 75% of cases of heritable pulmonary arterial hypertension (PAH).3 In the other 25% of families, either the mutation remains unknown, or it is in the ALK-1 or endoglin genes, SMAD 8 or caveolin 1.4 Undoubtedly, other rarer mutations that cause disease will be found.
  • GUEST EDITOR'S MEMO In this issue of Advances in Pulmonary Hypertension we focus on the Scientific Sessions that occurred in June 2014 at PHA's 2014 International PH Conference. The focus of the Scientific Sessions that occurred in June 2014 at PHA's 2014 International PH Conference. The focus of the Scientific Sessions was, "New Testaments and Targets in Pulmonary Hypertension."
  • PH Roundtable: Perspectives on PHA’s 10th International PH Conference
  • Pulmonary Hypertension Roundtable: Reflections on the Scientific Sessions Following PHA's International PH Conference and Scientific Sessions in Indianapolis on June 20-22, 2014, a group of clinicians gathered by phone to discuss the highlights of the meeting they would take to their practice. Guest editor Anna R. Hemnes, MD, Assistant Professor of Medicine and Assistant Director, Pulmonary Vascular Center at Vanderbilt University and Chair of the Scientific Sessions, facilitated the call. Discussants were: Raymond Benza, MD; Karen Fagan, MD; Steven M. Kawut, MD; Jeffrey S. Sager, MD, MSc; Glenna Traiger, RN, MS, CNS-BC.
  • Pulmonary Hypertension Roundtable: The Challenging Spectrum of PH in Liver and Kidney Transplantation Patients On August 16, 2013, a group of physicians with clinical expertise related to management of pulmonary hypertension (PH) patients who are undergoing evaluation for or having liver or kidney transplantation was convened by telephone to discuss this challenging topic. These complex patients represent a spectrum of clinical types of PH and require complete evaluations utilizing a team-oriented and multidisciplinary approach to ensure appropriate treatment and safe transplantation. Facilitated by the guest editors of this issue, Charles Burger, MD, and Paul Forfia, MD, discussants included Michael Krowka, MD, Professor of Medicine, Pulmonary Division, Mayo Clinic, Rochester, Minnesota; Jose´ Diaz-Go´mez, MD, Medical Director-ICU, Departments of Anesthesiology and Critical Care, Mayo Clinic, Jacksonville, Florida; Anna Hemnes, MD, Assistant Professor, Assistant Director, Pulmonary Vascular Disease Program Vanderbilt University Medical Center, Nashville, Tennessee; and Michael Mathier, MD, Assistant Professor of Medicine, Director, Pulmonary Hypertension Program, and Associate Director, Cardiovascular Fellowship Program of the University of Pittsburgh Medical Center.

Presentations